In Brief This Week: Trovagene; BG Medicine; Amoy Diagnostics; AITbiotech; Quest Diagnostics; Pressure BioSciences; Zellkraftwerk | GenomeWeb

NEW YORK (GenomeWeb News) – Trovagene said this week that it will collaborate with researchers at the University of Texas MD Anderson Cancer Center on detecting transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers. The researchers will use Trovagene's transrenal DNA detection technology to evaluate BRAF mutation status in urine compared to tissue biopsy. The partners previously collaborated on detecting transrenal KRAS mutations in the urine of patients with pancreatic cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.